Biolegend, 127602, Purified anti-mouse Ly-6G Antibody, 500μg

Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, is expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
500μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Ly-6G transfected EL-4J cell line.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested IHC-F - Verified IHC - Reported in the literature, not verified in house IHC-P, SB - Community verified
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C15. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A815. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.416. Additional reported applications (for the relevant formats) include: immunohistochemistry9 of frozen sections10 and paraffin-embedded sections11, depletion4, 12-14, and spatial biology (IBEX)20,21. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for in vivo studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662).
Additional Product Notes: This product has been verified for IHC-P (Immunohistochemistry - formalin-fixed paraffin-embedded tissues) on the NanoString GeoMx® Digital Spatial Profiler. The GeoMx® enables researchers to perform spatial analysis of protein and RNA targets in FFPE and fresh frozen human and mouse samples. For more information about our spatial biology products and the GeoMx® platform, please visit our spatial biology page.
Application References(PubMed link indicates BioLegend citation): Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC) Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC) Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC) Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC) Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC) Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC) Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete) Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete) Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete) Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed Ma C, et al. 2012. J. Leukoc. Biol. 92:1199. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Lalazar G, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G377 - G386. PubMed Hernández-Santana YE, et al. 2020. Life Sci Alliance. 3:00. PubMed Davies M, et al. 2017. PLoS Pathogens. 13(6):e1006435. PubMed Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed Shen S, et al. 2018. Front Immunol. 1.06875. PubMed Guiducci C, et al. 2010. J Exp Med. 207:2931. PubMed Diamantopoulou Z, et al. 2022. Nature. 607:156. PubMed Sheng YH, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:789. PubMed Zhang C, et al. 2022. Cells. 11:. PubMed Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed Huang X, et al. 2023. Glia. 71:1607. PubMed Ranoa DRE, et al. 2023. J Immunother Cancer. 11:. PubMed Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed Liao X, et al. 2022. Front Immunol. 12:768813. PubMed Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed Bruce DW, et al. 2021. Blood Adv. 5:4578. PubMed Poon C, et al. 2022. Focus (Am Psychiatr Publ). 20:100. PubMed Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed Cai S, et al. 2020. Sci Rep. 10:14249. PubMed Calcagno DM, et al. 2020. Sci Immunol. 5: . PubMed Chipashvili O, et al. 2021. Cell Host Microbe. 29:1649. PubMed Bettke JA, et al. 2022. Infect Immun. 90:e0007022. PubMed Kopanja D, et al. 2022. Cancer Res. 82:2458. PubMed Poller WC, et al. 2022. Nature. 607:578. PubMed Pannunzio B, et al. 2022. Cells. 11: . PubMed Bathini P, et al. 2022. Biomolecules. 12: . PubMed Abdelnabi MN, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:1269. PubMed Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed Zhai M, et al. 2022. Nat Commun. 13:7500. PubMed Zia S, et al. 2022. Mol Neurodegener. 17:82. PubMed Mikkelsen RB, et al. 2022. iScience. 25:105683. PubMed Montilla A, et al. 2023. Cell Death Dis. 14:16. PubMed DeRoo E, et al. 2023. Commun Biol. 6:130. PubMed Hu R, et al. 2023. Cell Death Discov. 9:50. PubMed Reglero-Real N, et al. 2021. Immunity. :. PubMed Yago T, et al. 2015. J Exp Med. 212: 1267 - 1281. PubMed Choudhury SR, et al. 2020. Cell. 178(5):1205-1221.e17.. PubMed Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed Kapellos TS, et al. 2019. FASEB J. 33:6154. PubMed Bhatt K, et al. 2018. mSphere. 3:e00352. PubMed Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed Wang B et al. 2018. Cell stem cell. 22(2):206-220 . PubMed Ringgaard L, et al. 2020. Sci Adv. 6:. PubMed Qu M, et al. 2022. Cell Death Discov. 8:375. PubMed Pilling D, et al. 2022. Respir Res. 23:215. PubMed Ho TY, et al. 2021. Mol Ther Oncolytics. 22:85. PubMed Her Z, et al. 2015. EMBO Mol Med. 7:24. PubMed Simon N, et al. 2019. JCI Insight. 4:. PubMed Boeckel SRV, et al. 2019. Sci Rep. 9:7356. PubMed Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed Ajona D, et al. 2017. Cancer Discov. 0.773611111. PubMed Goel S, et al. 2017. Nature. 548:471. PubMed Rehm SRT, et al. 2019. Sci Rep. 9:9925. PubMed Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed Elshal M, et al. 2022. Inflammopharmacology. :. PubMed Yao W, et al. 2019. Nature. 568:410. PubMed Whyte W, et al. 2022. Nat Commun. 13:4496. PubMed Han J, et al. 2022. FEBS J. 289:417. PubMed Cheng WJ, et al. 2021. Front Pharmacol. 12:762829. PubMed Karhadkar TR, et al. 2021. J Pharmacol Exp Ther. 376:106. PubMed Rogic A, et al. 2021. Nat Commun. 12:6889. PubMed Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed Juttukonda LJ, et al. 2017. Cell Host Microbe. 22:531. PubMed Verma M, et al. 2018. Brain Behav Immun. 69:223. PubMed Düsedau HP, et al. 2019. Glia. 67:193. PubMed Meng L, et al. 2021. Front Oncol. 11:691705. PubMed Kleinholz CL, et al. 2021. Sci Rep. 11:15071. PubMed Scott NR, et al. 2020. J Clin Invest. 130:3098. PubMed Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed Wang Y, et al. 2019. Cell. 179:1144. PubMed McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed Qu S, et al. 2018. Int J Cancer. 8:6685. PubMed Nakamizo S,et al. 2017. Sci Rep. . 10.1038/s41598-017-14292-1. PubMed Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed Sugita J, et al. 2021. Nat Commun. 12:1910. PubMed Andrade E, et al. 2013. J Immunol. 191:4759. PubMed Ng L, et al. 2011. J Invest Dermatol. 131:2058. PubMed Vallelian F, et al. 2018. Pharmacol Res Perspect. 15:5422. PubMed Nolin JD, et al. 2017. JCI Insight. 2:e94929. PubMed Silvestre-Roig C, et al. 2019. Nature. 569:236. PubMed Guiducci E, et al. 2018. Front Immunol. 1.467361111. PubMed O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed Chen L, et al. 2020. Front Immunol. 11:584458. PubMed Louwe MC, et al. 2020. JACC Basic Transl Sci. 1.048611111. PubMed Karhadkar TR, et al. 2021. PLoS One. 16:e0245924. PubMed Ilyas G, et al. 2015. J Hepatol. Available online 29 August 2015. PubMed Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed Gu H, et al. 2018. Aging (Albany NY). 1.525694444. PubMed Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed Chudnovskiy A et al. 2016. Cell. 167(2):444-456 . PubMed Perdomo J, et al. 2019. Nat Commun. 10:1322. PubMed Bence Daniel et al. 2018. Immunity. 49(4):615-626 . PubMed Snell LM, et al. 2018. Immunity. 49:678. PubMed Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed Maybin JA, et al. 2018. Nat Commun. 9:295. PubMed Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed Metz H, et al. 2016. Proc Natl Acad Sci U S A. 113: 8795 - 8800. PubMed Okubo K, et al. 2021. Cell Reports. 35(7):109142. PubMed Danobeitia J, et al. 2017. PLoS One.. 10.1371/journal.pone.0183701. PubMed Meers GK, et al. 2018. PLoS One. 13:e0190846. PubMed Mottahedin A, et al. 2017. J Leukoc Biol. 101:297. PubMed Schmid AS, et al. 2018. Rheumatology (Oxford). 57:748. PubMed Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed Vito A, et al. 2021. Commun Biol. 4:859. PubMed Kroh A, et al. 2020. Gastroenterol Res Pract. 7347068:2020. PubMed McCartney-Francis N, et al. 2014. J Leukoc Biol. 96:917. PubMed Reeves R 2010. J Immunol. 185:4904. PubMed Peterson LW, et al. 2017. J Exp Med. 214:3171. PubMed Kapellos TS, et al. 2017. Mediators Inflamm. 2017:4315412. PubMed Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed Borges TJ, et al. 2018. Nat Commun. 9:3482. PubMed Hoves S, et al. 2018. J Exp Med. 215:859. PubMed Vu LT, et al. 2019. J Extracell Vesicles. 8:1599680. PubMed Ottone OK, et al. 2022. Front Immunol. 13:882407. PubMed Hu G, et al. 2021. Nat Commun. 12:773. PubMed Otxoa–de–Amezaga A, et al. 2019. Acta Neuropathol. 137:321. PubMed Davies CL, et al. 2019. Front Immunol. 10:1048. PubMed Paharik AE, et al. 2017. Cell Host Microbe. 22:746. PubMed Johnson SA, et al. 2021. Eur J Immunol. 51:3228. PubMed Poon C, et al. 2021. Theranostics. 11:1655. PubMed Lim CS, et al. 2020. Front Immunol. 11:1186. PubMed Yoon S, et al. 2020. Antioxidants (Basel). 10:. PubMed Karhadkar TR, et al. 2020. bioRxiv. . PubMed Jung H, et al. 2019. Autophagy. 15:1990. PubMed Shevchenko MA, et al. 2018. J Immunol Res. 8:53. PubMed Burr AC, et al. 2021. J Inflamm Res. 14:4035. PubMed Zhao D, et al. 2020. Cancer Discov. 10:1374. PubMed Fino KK, et al. 2017. Sci Rep. 5.334722222. PubMed Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed Chipashvili O, et al. 2022. STAR Protoc. 3:101167. PubMed González LA, et al. 2021. Front Immunol. 12:638917. PubMed Li J, et al. 2021. Front Immunol. 12:710406. PubMed Goh W, et al. 2020. Cell Rep. 33:108285. PubMed Kim D, et al. 2019. Immune Netw. 19:e32. PubMed Otxoa–de–Amezaga A, et al. 2019. Stroke. 50:1548. PubMed Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed Jiao L, et al. 2021. J Pathol. 255:270. PubMed Liu A, et al. 2021. J Nanobiotechnology. 19:280. PubMed Sacramento L, et al. 2015. Infect Immun . 83: 4604 - 4616. PubMed Bennewitz MF, et al. 2020. Blood Adv. 0.351388889. PubMed Wilson ZS, et al. 2020. Sci Rep. 10:2142. PubMed Bianchi–Frias D, et al. 2019. Mol Cancer Res. 17:321. PubMed Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed Ferrer-Font L, et al. 2020. Elife. 9:. PubMed Pedragosa J, et al. 2021. Exp Neurol. 346:113865. PubMed Stempel H, et al. 2016. J Biol Chem. 291: 9762-9775. PubMed Sumagin R, et al. 2010. J Immunol. 185:7057. PubMed Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed Chen M, et al. 2019. Cell Stem Cell. 25:501. PubMed McArthur S, et al. 2020. J Clin Invest. 130:1156. PubMed Lin L, et al. 2018. J Invest Dermatol. 138:1032. PubMed Scutts SR, et al. 2018. Cell Rep. 25:1953. PubMed Bonnart C, et al. 2017. Parasite Immunol.. 10.1111/pim.12489. PubMed Li N, et al. 2022. Nat Commun. 13:7281. PubMed Liu J, et al. 2022. Stem Cell Res Ther. 13:247. PubMed Andersen MJ, et al. 2022. Elife. 11:. PubMed Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed Takeuchi Y, et al. 2021. Sci Rep. 11:18679. PubMed Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed Carper MB, et al. 2019. Cell Rep. 29:1660. PubMed Deng M, et al. 2019. J Exp Med. 216:2838. PubMed Ipseiz N, et al. 2020. EMBO J. 39:e103454. PubMed Dey P, et al. 2020. Cancer Discov. 10:608. PubMed Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed Burger ML, et al. 2021. Cell. 184:4996. PubMed Tilburg J, et al. 2020. J Thromb Haemost. 1.940277778. PubMed Prows DR, et al. 2020. American Journal of Physiology-Heart and Circulatory Physiology. 317(2):H405-H414.. PubMed Zhao Z, et al. 2019. J Immunol Res. 2019:9561350. PubMed Kao TI, et al. 2021. Br J Pharmacol. 178:4069. PubMed James BN, et al. 2021. J Allergy Clin Immunol. 147:1936. PubMed Hunt LC, et al. 2021. Cell Rep. 37:109971. PubMed Raccosta L, et al. 2013. J Exp Med. 210:1711. PubMed An Y et al. 2018. Cell reports. 25(3):702-714 . PubMed Kikuchi K, et al. 2018. J Immunol. 201:635. PubMed Luo J, et al. 2019. Clin Cancer Res. 25:808. PubMed Zhang M, et al. 2018. Front Immunol. 2.285416667. PubMed Leist SR, et al. 2019. PLoS One. 14:e0220126. PubMed Cain D, et al. 2011. PLoS One. 6:e19957. PubMed Song M, et al. 2020. Nat Commun. 11:6298. PubMed Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed Kang SH, et al. 2018. Oncoimmunology. 8:e1515057. PubMed Regan–Komito D, et al. 2017. Front Immunol. 1.459027778. PubMed Watanabe K, et al. 2017. PLoS Pathog.. 10.1371/journal.ppat.1006513. PubMed
RRID: AB_1089179 (BioLegend Cat. No. 127601) AB_1089180 (BioLegend Cat. No. 127602)
Structure: A 21-35 kD GPI-anchorded membrane protein
Distribution: Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.
Cell Type: Granulocytes, Macrophages, Monocytes
Biology Area: Immunology, Innate Immunity
Antigen References: Fleming TJ, et al. 1993. J. Immunol. 151:2399.
Gene ID: 546644
UniProt: View information about Ly-6G on UniProt.org
Clone: 1A8
Regulatory Status: RUO
Other Names: Lymphocyte antigen 6 complex, locus G
Isotype: Rat IgG2a, κ
Q: If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?
A: It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.
Q: Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?
A: Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.
Q: Are other fluorophores compatible with IBEX?
A: Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.
Q: The same antibody works in one tissue type but not another. What is happening?
A: Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.
Q: How can I be sure the staining I’m seeing in my tissue is real?
A: In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.